Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Withdraws Adagrasib/Cetuximab Approval in KRAS G12C-Mutated CRC

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at cancernetwork.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

The FDA has withdrawn accelerated approval for the combination of adagrasib and cetuximab for KRAS G12C-mutated colorectal cancer after the KRYSTAL-10 trial failed to demonstrate improved survival outcomes.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a major market exit in colorectal cancer treatment as FDA pulls your drug combo's approval. Redirect focus to alternative KRAS G12C therapies or indications where regulatory status remains intact.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-withdrawaladagrasibcetuximabkras-g12ccolorectal-cancer